vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Thermon Group Holdings, Inc. (THR). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $147.3M, roughly 1.9× Thermon Group Holdings, Inc.). Thermon Group Holdings, Inc. runs the higher net margin — 12.4% vs -45.7%, a 58.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 9.6%). Thermon Group Holdings, Inc. produced more free cash flow last quarter ($13.1M vs $-54.2M).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Thermon Group Holdings, Inc. is a global provider of engineered thermal management solutions, specializing in heat tracing systems, heating cables, temperature monitoring controls, and associated installation support services. It serves core industrial segments including oil and gas, chemical processing, power generation, and food and beverage, with operating bases across North America, Europe, Asia-Pacific, and Latin America.
GH vs THR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $147.3M |
| Net Profit | $-128.5M | $18.3M |
| Gross Margin | 64.6% | 46.6% |
| Operating Margin | -43.0% | 18.1% |
| Net Margin | -45.7% | 12.4% |
| Revenue YoY | 39.4% | 9.6% |
| Net Profit YoY | -15.8% | -1.3% |
| EPS (diluted) | $-1.01 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $147.3M | ||
| Q3 25 | $265.2M | $131.7M | ||
| Q2 25 | $232.1M | $108.9M | ||
| Q1 25 | $203.5M | — | ||
| Q4 24 | $201.8M | — | ||
| Q3 24 | $191.5M | — | ||
| Q2 24 | $177.2M | — | ||
| Q1 24 | $168.5M | — |
| Q4 25 | $-128.5M | $18.3M | ||
| Q3 25 | $-92.7M | $15.0M | ||
| Q2 25 | $-99.9M | $8.6M | ||
| Q1 25 | $-95.2M | — | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | — | ||
| Q2 24 | $-102.6M | — | ||
| Q1 24 | $-115.0M | — |
| Q4 25 | 64.6% | 46.6% | ||
| Q3 25 | 64.7% | 46.4% | ||
| Q2 25 | 65.0% | 44.1% | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 18.1% | ||
| Q3 25 | -37.3% | 16.4% | ||
| Q2 25 | -45.9% | 10.8% | ||
| Q1 25 | -54.6% | — | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | — | ||
| Q2 24 | -56.8% | — | ||
| Q1 24 | -59.2% | — |
| Q4 25 | -45.7% | 12.4% | ||
| Q3 25 | -35.0% | 11.4% | ||
| Q2 25 | -43.0% | 7.9% | ||
| Q1 25 | -46.8% | — | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | — | ||
| Q2 24 | -57.9% | — | ||
| Q1 24 | -68.2% | — |
| Q4 25 | $-1.01 | $0.55 | ||
| Q3 25 | $-0.74 | $0.45 | ||
| Q2 25 | $-0.80 | $0.26 | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | — | ||
| Q2 24 | $-0.84 | — | ||
| Q1 24 | $-0.94 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $46.9M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $538.7M |
| Total Assets | $2.0B | $816.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $46.9M | ||
| Q3 25 | $580.0M | $29.7M | ||
| Q2 25 | $629.1M | $36.5M | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $538.7M | ||
| Q3 25 | $-354.5M | $515.2M | ||
| Q2 25 | $-305.5M | $509.3M | ||
| Q1 25 | $-250.8M | — | ||
| Q4 24 | $-139.6M | — | ||
| Q3 24 | $-60.1M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $68.3M | — |
| Q4 25 | $2.0B | $816.7M | ||
| Q3 25 | $1.3B | $778.2M | ||
| Q2 25 | $1.3B | $765.3M | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.7B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $18.0M |
| Free Cash FlowOCF − Capex | $-54.2M | $13.1M |
| FCF MarginFCF / Revenue | -19.3% | 8.9% |
| Capex IntensityCapex / Revenue | 9.9% | 3.3% |
| Cash ConversionOCF / Net Profit | — | 0.98× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $18.0M | ||
| Q3 25 | $-35.4M | $7.4M | ||
| Q2 25 | $-60.3M | $10.7M | ||
| Q1 25 | $-62.7M | — | ||
| Q4 24 | $-64.5M | — | ||
| Q3 24 | $-51.1M | — | ||
| Q2 24 | $-94.0M | — | ||
| Q1 24 | $-30.3M | — |
| Q4 25 | $-54.2M | $13.1M | ||
| Q3 25 | $-45.8M | $4.4M | ||
| Q2 25 | $-65.9M | $8.3M | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | 8.9% | ||
| Q3 25 | -17.3% | 3.3% | ||
| Q2 25 | -28.4% | 7.6% | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | 3.3% | ||
| Q3 25 | 3.9% | 2.3% | ||
| Q2 25 | 2.4% | 2.2% | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | — | 0.98× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
THR
| Other | $73.7M | 50% |
| Transferred At Point In Time | $56.1M | 38% |
| Transferred Over Time | $17.5M | 12% |
